The activation of TLR9 on DCs and plasmacytoid DCs promotes the secretion of a large amount of type I IFN, which has both direct (tumor cell inhibitory effect) and indirect (antitumor immune responses) effects on cancer cells and is most evident in the early stages of antitumor immune responses [38]. Here, TLR9 is linked to cancer.